|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
92.46(B) |
Last
Volume: |
505,652 |
Avg
Vol: |
771,513 |
52
Week Range: |
$692.45 - $993.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
41,535 |
84,942 |
120,451 |
283,828 |
Total Sell Value |
$39,627,604 |
$77,255,398 |
$106,928,922 |
$220,981,114 |
Total People Sold |
9 |
13 |
15 |
17 |
Total Sell Transactions |
21 |
38 |
54 |
116 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sing George L |
Director |
|
2024-02-08 |
4 |
OE |
$413.33 |
$206,665 |
D/D |
500 |
26,849 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2024-02-07 |
4 |
S |
$950.00 |
$950,000 |
D/D |
(1,000) |
38,543 |
|
5% |
|
Stahl Neil |
EVP Research and Development |
|
2024-02-07 |
4 |
S |
$947.34 |
$7,637,954 |
D/D |
(8,037) |
52,019 |
|
5% |
|
Pitofsky Jason |
Vice President, ControllerOffi |
|
2024-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,204 |
|
-5% |
|
Mccourt Marion |
EVP Commercial |
|
2024-02-05 |
4 |
S |
$934.71 |
$934,710 |
D/D |
(1,000) |
13,789 |
|
5% |
|
Stahl Neil |
EVP Research and Development |
|
2024-02-02 |
4 |
D |
$956.65 |
$21,728,391 |
D/D |
(22,713) |
60,056 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2024-02-02 |
4 |
OE |
$399.66 |
$12,289,545 |
D/D |
30,750 |
82,769 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-02-02 |
4 |
D |
$956.65 |
$268,819 |
D/D |
(281) |
23,693 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-02-02 |
4 |
OE |
$378.98 |
$151,592 |
D/D |
400 |
23,974 |
|
- |
|
Ryan Arthur F |
Director |
|
2024-02-01 |
4 |
AS |
$939.53 |
$95,422 |
D/D |
(100) |
18,382 |
|
-8% |
|
Mccourt Marion |
EVP Commercial |
|
2024-02-01 |
4 |
AS |
$945.61 |
$258,152 |
D/D |
(273) |
14,789 |
|
-8% |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-31 |
4 |
D |
$953.42 |
$268,864 |
D/D |
(282) |
23,574 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-31 |
4 |
OE |
$378.98 |
$151,592 |
D/D |
400 |
23,856 |
|
- |
|
Bassler Bonnie L |
Director |
|
2024-01-30 |
4 |
AS |
$959.00 |
$793,093 |
D/D |
(827) |
1,382 |
|
-8% |
|
Bassler Bonnie L |
Director |
|
2024-01-30 |
4 |
OE |
$380.95 |
$315,046 |
D/D |
827 |
2,209 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-24 |
4 |
D |
$951.26 |
$334,844 |
D/D |
(352) |
23,456 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-24 |
4 |
OE |
$378.98 |
$189,490 |
D/D |
500 |
23,808 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-23 |
4 |
D |
$948.50 |
$736,036 |
D/D |
(776) |
23,308 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-23 |
4 |
OE |
$378.98 |
$416,878 |
D/D |
1,100 |
24,084 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2024-01-23 |
4 |
D |
$948.50 |
$7,179,197 |
D/D |
(7,569) |
19,291 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2024-01-23 |
4 |
OE |
$399.66 |
$4,776,650 |
D/D |
10,000 |
22,874 |
|
- |
|
Goldstein Joseph L |
Director |
|
2024-01-23 |
4 |
AS |
$950.00 |
$2,571,650 |
D/D |
(2,707) |
6,382 |
|
-7% |
|
Goldstein Joseph L |
Director |
|
2024-01-23 |
4 |
OE |
$625.60 |
$1,693,499 |
D/D |
2,707 |
9,089 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-17 |
4 |
D |
$932.34 |
$330,048 |
D/D |
(354) |
22,984 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2024-01-17 |
4 |
OE |
$378.98 |
$189,490 |
D/D |
500 |
23,338 |
|
- |
|
1366 Records found
|
|
Page 2 of 55 |
|
|